http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
앉은부채(Symplocarpus renifolius Schott) 뿌리의 성분
염정록,박동우,Youm, Jeong-Rok,Park, Dong-Woo 한국생약학회 1997 생약학회지 Vol.28 No.3
From the root of Symplocarpus renifolius, four compounds were isolated and their structure was elucidated by chemical and spectroscopic methods. They were identified as ${\beta}-sitosterol$ (compound 1), asparagine (compound 2), isocorydine (compound 3) and 3-hydroxymethyl-4-phenyl phenoxy carboxylic acid glucopyranosyl ester (compound 4). These compounds were firstly isolated from roots of Symplocarpus renifolius. Compound 4 was identified as a new compound, named as symplocarposide.
13C NMR 화학 Shift 측정에 미치는 TMS의 거동
염정록(Jeong Rok Youm) 대한약학회 1989 약학회지 Vol.33 No.3
A method is presented for calculating the 13C chemical shifts produced in liquid solution by referenced relative to RF frequency. The method is useful to get the real variations of chemical shifts in magnetic field by eliminating the affects of the variation of a reference substance.
alpha-치환 톨루엔 유도체의 13C NMR 화학 Shift
염정록(Jeong Rok Youm) 대한약학회 1988 약학회지 Vol.32 No.3
13C NMR chemical shifts for 18 alpha-susbstituted toluenes at high dilution in CCl4 solution have been determined. Substituents are as follows: H, Me, Et, n-Pr, iso-Pr, Ph, F, Cl, Br, NH2, NHMe, NMe2, OH, OMe, OCOMe, C02Me, C02Et, CN. Those chemical shifts of the methylene carbon of the toluene and the alpha-carbon of the n-butane systems are correlated well. (r=.975, slope=.962)
앉은부채(Symplocarpus renifolius Schott) 뿌리의 생리활성
이승목,염정록,박동우,Lee, Seung-Mok,Youm, Jeong-Rok,Park, Dong-Woo 한국생약학회 1997 생약학회지 Vol.28 No.4
Symplocarpus renifolius, a folk medicinal herb has been used for treatment of hypertension, rheumatis, tetanus, ringworm, cough and epilepsy in north and middle part of Korea. The extracts from the root of S. renifolius were evaluated for antibacterial, antihypertensive and analgesic activities. The crude extract of the root of S. renifolius showed antibacterial activity against Gram(+) bacteria and dose dependantly decrease the blood pressure of SHR. The chloroform extract of the roots of S. renifolius was also exibits analgesic action in mice.
은행잎중 Flavonol Glycoside 성분의 계절별 함량 변화에 관한 연구
강규선,염정록,강삼식,Kang, Gyu-Sun,Youm, Jeong-Rok,Kang, Sam-Sik 한국생약학회 1993 생약학회지 Vol.24 No.1
The seasonal variations of the major six flavonol glycosides(kaempferol 2,6-dirhamnosyl glucoside, quercetin 3-O-rutinoside, kaempferol 3-O-rutinoside, isorhamnetin 3-O-rutinoside, quercetin 3-O-coumaroyl glucorhamnoside and kaempferol 3-O-coumaroyl glucorhamnoside) in Ginkgo biloba leaves were investigated. The contents were determined by HPLC on reversed phase $C_{18}$ column. This result showed that the percentage of six flavonol glycosides decreased during the season from 1.57% in May to 0.39% in November. The content of each flavonol glycoside indicated a similar tendency to decrease. However, the contents of rutinosides of kaempferol, quercetin and isorhamnetin fluctuated markedly than those of coumaroyl glucorhamnosides of kaempferol and quercetin and kaempferol 2,6-dirhamnosyl glucoside.
박상희,염정록,장일무,Park, Sang-Hi,Youm, Jeong-Rok,Chang, Il-Moo 한국생약학회 1991 생약학회지 Vol.22 No.2
In the preceding paper, it was reported that total 63 traditional Korean herbal medicines listed in the Korean Pharmacopoeia and Korean Natural Drug Standards were found to be different plants in terms of systematic botany when those were compared with other two countries' drug compendia, Chinese Pharmacopoeia, Japanese Pharmacopoeia and Japanese Natural Drug Standards. Among 63 traditional Korean herbal drugs, 28 items were subject to the chemical identification test by using official methods that are described in the Korean Pharmacopoeia and the Korean Natural Drug Standards. In addition, 5 items were also tested by using the official methods described in Chinese and Japanese drug compendia, since there are no official chemical tests available in the Korean drug compendia. It was found that most of chemical tests appeared to be suitable. It was noted that the chemical test for Atractylodis Rhizoma(蒼朮) was incorrect and unapplicable. Those chemical tests for Clematidis Radix(威靈仙), Rubi Fructus(覆盆子) and Viticis Fructus(蔓荊子) are desirable to be revised for more accurate identification.
은행잎 중 Biflavone의 계절별 함량 변화에 관한 연구
장수경,염정록,강삼식,Chang, Soo-Kyung,Youm, Jeong-Rok,Kang, Sam- Sik 한국생약학회 1993 생약학회지 Vol.24 No.1
The seasonal variations of five biflavones from Ginkgo biloba leaves from May to November were investigated by a reversed phase HPLC method. The total amount of biflavones was increased with time to reach its maximum in yellow autumnal leaves. Each biflavone showed a similar tendency. It increased rapidly about 3.1-fold from May to June and thereafter gradually increased about 2.5-fold. The ratio of each biflavone content to the total amount of biflavones was in the order of as follows: isoginkgetin>sciadopitysin>bilobetin>ginkgetin>amentoflavone.
액토스정<sup>®</sup>(피오글리타존 30 mg)에 대한 염산피오글리타존정의 생물학적동등성
염혜선,이태호,염정록,송진호,한상범,Yeom, Hyesun,Lee, Tae Ho,Youm, Jeong-Rok,Song, Jin-Ho,Han, Sang Beom 한국분석과학회 2009 분석과학 Vol.22 No.1
The bioequivalence of two pioglitazone tablets, Actos$^{(R)}$ tablet (Takeda Chemical Industries, reference drug) and Pioglitazone tablet (Boryung Company, test drug) was evaluated according to the guidelines of Korea Food and Drug Administration. Twenty-eight healthy male Korean volunteers received each medicine (pioglitazone dose of 30 mg) in a $2{\times}2$ crossover study with one week washout interval. After drug administration, blood samples were collected at specific time intervals from 0-36 hours. The plasma concentrations of pioglitazone were determined by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). The total chromatographic run time was 5 min and calibration curves were linear over the concentration range of 5-2000 ng/mL for pioglitazone. The method was validated for selectivity, sensitivity, linearity, accuracy and precision. The pharmacokinetic parameters were determined from the plasma concentration-time profiles of both formulations. The primary calculated pharmacokinetic parameters were compared statistically to evaluate bioequivalence between the two preparations. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for Pioglitazone tablet and Actos$^{(R)}$ tablet were log0.9422~log1.1040 and log0.9200~log1.1556, respectively. Based on the statistical considerations, we can conclude that the test drug, Pioglitazone tablet was bioequivalent to the reference drug, Actos$^{(R)}$ tablet.
리피토정<sup>®</sup> (아토르바스타틴 20 mg)에 대한 아토르바정<sup>®</sup>의 생물학적동등성
임현균,이태호,이재현,염정록,송진호,한상범,Lim, Hyun-Kyun,Lee, Tae-Ho,Lee, Jae-Hyun,Youm, Jeong-Rok,Song, Jin-Ho,Han, Sang-Beom 한국약제학회 2008 Journal of Pharmaceutical Investigation Vol.38 No.2
The present study describes the evaluation of the bioequivalence of two atorvastatin tablets, Lipitor $Tablet^{(R)}$ (Pfizer, reference drug) and Atorva $Tablet^{(R)}$ (Yuhan, test drug), according to the guidelines of Korea Food and Drug Administration (KFDA). Forty-nine healthy male Korean volunteers received each medicine at the atorvastatin dose of 40 mg in a $2{\times}2$ crossover study with a two weeks washout interval. After drug administration, serial blood samples were collected at a specific time interval from 0-48 hours. The plasma atorvastatin concentrations were monitored by an high performance liquid chromatography -tandem mass spectrometer (LC-MS/MS) employing electrospray ionization technique and operating in multiple reaction monitoring (MRM) and positive ion mode. The total chromatographic run time was 4.5 min and calibration curves were linear over the concentration range of 0.1-100 ng/mL for atorvastatin. The method was validated for selectivity, sensitivity, linearity, accuracy and precision. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 48hr) was calculated by the linear log trapezoidal rule method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were complied trom the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_t$ and $C_{max}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for Atorva $Tablet^{(R)}$ / Lipitor $Tablet^{(R)}$ were ${\log}\;0.9413{\sim}{\log}\;1.0179$ and ${\log}\;0.831{\sim}{\log}\;1.0569$, respectively. These values were within the acceptable bioequivalence intervals of ${\log}\;0.8{\sim}{\log}\;1.25$. Based on these statistical considerations, it was concluded that the test drug, Atorva $Tablet^{(R)}$ was bioequivalent to the reference drug, Lipitor $Tablet^{(R)}$.